A10BJ03 - Lixisenatide |
Propably not porphyrinogenic |
PNP |
Important Information
Very common adverse reactions of lixisenatide that can be confused with an acute porphyric attack are nausea and vomiting. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Side effects
Very common adverse reactions of lixisenatide that can be confused with an acute porphyric attack are nausea and vomiting. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Lixisenatide is not metabolized by the cytochrome P450 system, and is not an inducer or an inhibitor of these enzymes.
Chemical description
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist.
Therapeutic characteristics
Lixisenatide is a glucagon-like peptide-1 receptor agonist used in diabetes type 2 in combination with other orally administered anti-diabetics. It is administered subcutaneously.
Metabolism and pharmakokinetics
Lixisenatide is a peptide and is therefore not hepatically metabolized but rather eliminated by glomerular filtration or proteolytic degradation. Interactions involving cytochrome P450 isoenzymes are not expected (Hurren 2012). In in vitro studies, lixisenatide did not affect the activity of cytochrome P450 isozymes or human transporters tested (SPC).
References
- Scientific articles
- Bettge K, Kahle M et al. Occurrence of nausea, vomiting, and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab. 2016 Nov 9. doi: 10.1111/dom.12824. PMID 27860132. #3213
- Hurren KM, Pinelli NR. Drug-drug interactions with glucagon-like peptide-1 receptor agonists. Ann Pharmacother. 2012 May; 46(5):710-7. Epub 2012 Apr 17. PMID 22510669. #1134
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Lyxumia. #3214
Similar drugs
© NAPOS 2024